Brian Shields: AstraZeneca withdraws Lung Cancer Application for TROP2 – directed ADC
Brian Shields, Creator of KOL Pulse AI, shared a post on LinkedIn:
“PR professionals in Pharma need to pay close attention.
There was a very interesting turn of events recently for the clinical trial TROPION-Lung01 and trial sponsors AstraZeneca and Daiichi Sankyo US.
AstraZeneca recently announced that they were withdrawing a lung cancer application for their TROP2-directed ADC, Dato-DXd.
This is an interesting turn of events and really shows how the Digital Opinion Leaders may be playing a significant role in the FDA Approval process. Throughout the year, the PR of the TROPION-Lung01 trial sponsors seemed to be in opposition to the sentiment of Lung Cancer Digital Opinion Leaders during the Medical Congress cycle.
This could be seen in ASCO24 PR, and PR during the World Lung Cancer meeting in September.
Throughout both meetings, the Digital Opinion Leaders voted early and voted often against the data they were being presented.
Here’s an interactive timeline app of the Corporate PR vs the Digital Opinion Leader Sentiments.
Here’e a blog on the Digital Opinion Sentiments of TROPION-Lung01.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023